8.07
+5.91%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Regenxbio
From its filings with the US Securities and Exchange Commission
Regenxbio is based in Rockville, Maryland. Its shares trade on Nasdaq under the ticker RGNX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $170.4m and a net loss of $193.9m. At that date it held total assets of $453.0m and shareholders' equity of $102.7m. By business, License and Service [Member] brought in 91.7% of revenue, followed by Service [Member] at 8.3%.
We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our investigational gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects.
Our investigational gene therapies use adeno-associated virus (AAV) vectors from our proprietary gene delivery platform, which we call our NAV® Technology Platform. AAV vectors are non-replicating viral delivery vehicles that are not known to cause disease. Our NAV Technology Platform has consisted of exclusive rights to a large portfolio of AAV vectors (NAV Vectors), including commonly used AAV8 and AAV9. We believe this platform forms a strong foundation for our current clinical-stage programs and, with our ongoing research and development, we expect to continue to expand our platform and pipeline of potential AAV vector-based gene therapies. Our NAV Technology Platform is the foundation for commercial and investigational AAV therapeutics that have treated thousands of patients through our clinical pipeline and NAV licensees.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Sept 2015
- Employees
- 371
- Website
- regenxbio.com ↗
- Head office
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Kenneth MillsChairman of the Board, since 2009$5.5m
- Mr. Curran SimpsonPresident, Chief Executive Officer, Director, since 2015$4.8m
- Mr. Mitchell ChanChief Financial Officer, Executive Vice President, Principal Accounting Officer$3.2m
- Mr. Craig MalzahnExecutive Vice President - Product Development, Chief Technology Officer
- Dr. Olivier DanosExecutive Vice President, Chief Scientific Officer$3.0m
- Mr. Patrick ChristmasExecutive Vice President, Chief Strategy and Legal Officer$2.7m
- Dr. Stephen PakolaExecutive Vice President, Chief Medical Officer$2.7m
- Mr. Daniel TasseLead Independent Director$347,482
- Mr. Allan FoxDirector$337,482
- Dr. Jean BennettIndependent Director$324,982
- Dr. Alexandra GlucksmannIndependent Director$327,482
- Dr. A. N. KarabelasIndependent Director$339,982
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 51
- Social
- 87
- Governance
- 17
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Regenxbio Inc has a strong portfolio of gene therapy products that have shown promising results in clinical trials. This positions the company as a leader in the field of gene therapy.
- The company has a highly talented team of scientists and researchers who possess extensive expertise in gene therapy, giving them a competitive advantage in developing innovative treatments.
- Regenxbio Inc has formed strategic partnerships with major pharmaceutical companies, providing them with access to additional resources, expertise, and potential distribution channels.
Weaknesses
- One weakness of Regenxbio Inc is its heavy reliance on a limited number of product candidates. If any of these candidates fail in clinical trials or face regulatory hurdles, it could significantly impact the company's revenue and future prospects.
- The company's success heavily depends on the regulatory environment for gene therapy, which is subject to change and uncertainty. This poses a risk to the company's ability to bring its products to market.
Opportunities
- The growing demand for effective treatments in genetic diseases presents a significant opportunity for Regenxbio Inc. As the field of gene therapy continues to advance, the company has an opportunity to capture a larger market share.
- Expanding partnerships within the healthcare industry can open doors for collaborative research and development, allowing Regenxbio Inc to access new technologies and potential markets.
Threats
- One major threat to Regenxbio Inc is the intense competition in the gene therapy market. Other companies are also investing heavily in research and development, potentially resulting in similar or superior gene therapy products.
- Uncertainty surrounding intellectual property rights and potential legal disputes pose a threat to the company's ability to protect and monetize its gene therapy technologies and products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.